Cost of decentralized CAR T-cell production in an academic nonprofit setting.

International Journal of Cancer. Journal International Du Cancer
Tao RanMichael Schlander

Abstract

Chimeric antigen receptor (CAR) T-cell therapy is a promising immunotherapy with high acquisition costs, and it has raised concerns about affordability and sustainability in many countries. Furthermore, the current centralized production paradigm for the T cells is less than satisfactory. Therefore, several countries are exploring alternative T-cell production modes. Our study is based on the T-cell production experience in a nonprofit setting in Germany. We first identified the work steps and main activities in the production process. Then we determined the fixed costs and variable costs. Main cost components included personnel and technician salaries, expenditure on equipment, a clean room, as well as production materials. All costs were calculated in 2018 euros and converted into U.S. dollars. For a clean room with one machine for closed and automated manufacturing installed, annual fixed costs summed up to approximately €438 098 ($584 131). The variable cost per production was roughly €34 798 ($46 397). At the maximum capacity of one machine, total cost per product would be close to €60 000 ($78 849). As shown in the scenario analysis, if three machines were to be installed in the clean room, per production cost could be as...Continue Reading

References

Mar 30, 2010·The Oncologist·Patricia M Danzon, Erin Taylor
Dec 18, 2013·Immunological Reviews·Christian S Hinrichs, Steven A Rosenberg
Mar 29, 2014·The Cancer Journal·Sunitha Kakarla, Stephen Gottschalk
Aug 6, 2014·Nature Biotechnology·Nuala TrainorTim Smith
Oct 15, 2014·Expert Review of Pharmacoeconomics & Outcomes Research·Michael SchlanderAfschin Gandjour
Apr 28, 2016·Nature Reviews. Clinical Oncology·Danny N KhalilJedd D Wolchok
Jun 28, 2016·Molecular Therapy Oncolytics·Xiuyan Wang, Isabelle Rivière
Mar 16, 2017·Nature Reviews. Clinical Oncology·Vinay PrasadSham Mailankody
May 6, 2017·Journal of Market Access & Health Policy·Goran MedicMichiel Hemels
Aug 26, 2017·Biotechnology Journal·Nicole J PiscopoKrishanu Saha
Oct 5, 2017·JAMA : the Journal of the American Medical Association·Peter B BachLeonard B Saltz
Dec 27, 2017·Biotechnology Advances·Richard P HarrisonNicholas Medcalf
Jan 31, 2018·Cancer Immunology, Immunotherapy : CII·Angela M KrackhardtMartina Schüssler-Lenz
Feb 1, 2018·The New England Journal of Medicine·Shannon L MaudeStephan A Grupp
Feb 1, 2018·The New England Journal of Medicine·Jae H ParkMichel Sadelain
Mar 9, 2018·Nature·Elie Dolgin
Mar 24, 2018·Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research·James LomasMarta Soares
Apr 24, 2018·Expert Review of Pharmacoeconomics & Outcomes Research·George DranitsarisMark D Vincent
May 14, 2018·Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research·Michael SchlanderAfschin Gandjour
Jun 19, 2018·Best Practice & Research. Clinical Haematology·Adrian P Gee
Jun 19, 2018·Annals of Translational Medicine·George Tran, S Yousuf Zafar
Jul 5, 2018·The New England Journal of Medicine·Carl H June, Michel Sadelain
Aug 16, 2018·The New England Journal of Medicine·Peter B Bach
Sep 14, 2018·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·John K LinJeremy D Goldhaber-Fiebert
Oct 12, 2018·Biotechnology Journal·Xiaofeng DaiZhonghu Bai
Dec 14, 2018·Recent Results in Cancer Research. Fortschritte Der Krebsforschung. Progrès Dans Les Recherches Sur Le Cancer·Patricia M Danzon
Feb 9, 2019·Human Vaccines & Immunotherapeutics·January Salas-MckeeJoseph A Fraietta
May 3, 2019·The New England Journal of Medicine·Noopur RajeJames N Kochenderfer
Mar 1, 2018·Nature·Elie Dolgin
Apr 4, 2020·The New England Journal of Medicine·Michael WangPatrick M Reagan

❮ Previous
Next ❯

Citations

May 2, 2021·Biotechnology Advances·Laurens RaesKevin Braeckmans
May 4, 2021·Current Hematologic Malignancy Reports·Melanie SchwerdtfegerSebastian Kobold
May 29, 2021·The Lancet. Haematology·Niels W C J van de DonkKwee Yong

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.